SoftBank Vision Fund owns more than 40% of the precision cancer drug developer, which raised $400m approximately 18 months ago.
US-based oncology therapy developer Relay Therapeutics filed on Wednesday to raise up to $200m in an initial public offering that will allow telecommunications firm SoftBank and internet technology group Alphabet to exit.
Relay is developing targeted small molecule cancer drugs using discoveries in protein motion and how it relates to the function of proteins that had previously been regarded as undruggable.
Part of the IPO proceeds will fund phase 1 and 1b clinical trials for a drug candidate called…
